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ABSTRAK
Plasmasitoma ekstramedulari adalah komplikasi myeloma berbilang yang sangat 
jarang berlaku. Kami melaporkan kes seorang wanita berumur 56 tahun yang 
menghidap myeloma berbilang yang telah mengalami bengkak pada mata kiri. Ia 
menyebabkan bola mata beliau tersembul, luka pada kornea dan juga kemerosotan 
penglihatan. Biopsi tisu menunjukkan perebakan plasma sel neoplastik yang positif 
kepada CD138 dan rantai ringan Kappa yang menepati ciri-ciri plasmasitoma. 
Setelah melalui rawatan radio-kemoterapi, pembengkakan mata susut dengan 
ketara sekali namun kemerosotan penglihatan beliau tidak berubah.
Kata kunci:  ekstramedulari, myeloma berbilang, kecederaan saraf optic, plasmasitoma,  
proptosis
ABSTRACT
Extramedullary plasmacytoma is a rare complication from multiple myeloma. 
We report a 56-year-old lady with underlying multiple myeloma who developed 
swelling over the left eye. It caused a non-axial proptosis, exposure keratopathy 
and visual acuity of counting fingers. A tissue biopsy revealed infiltration of tissue 
fragments with neoplastic plasma cells positive for CD138 and Kappa light chain 
restrictions consistent with plasmacytoma. Following radio-chemotherapy, the 
mass shrunk tremendously but her visual outcome remained poor.
Keywords: extramedullary, multiple myeloma, optic nerve injuries, plasmacytoma, 
proptosis
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INTRODUCTION
Plasmacytoma is a solitary, localized 
tumor collection of clonal neoplastic 
plasma cells which produce 
monoclonal immunoglobulin (Adkins 
et al. 1997). It occurs primarily before the 
diagnosis of multiple myeloma (MM) is 
made; or as a secondary presentation 
of MM. These soft tissue tumors are 
commonly classified as either solitary 
plasmacytomas of the bone (SPB) or 
extramedullary plasmacytomas (EMP). 
While extramedullary plasmacytoma 
commonly occurs in the upper 
respiratory tract, involvement of 
the orbit, eyelid, ocular adnexa and 
conjunctiva occurs rarely (Lida et al. 
2005).
CASE REPORT
A 56-year-old Malay lady was 
diagnosed with multiple myeloma in 
April 2013 and received suboptimal 
treatment due to financial constraint. 
In 2015, she presented with a 3-wks 
history of left upper eyelid swelling. 
Within two weeks, the eyelid swelling 
doubled in size and was associated 
with proptosis, restriction of eye 
movement and poor vision in the left 
eye (Figure 1a). At the same time she 
was diagnosed with pathological right 
ulnar fracture with X-ray findings of 
multiple lytic lesion corresponding to 
myeloma bone disease (Figure 2a, 2c 
and 2d). She also had a previous history 
of pathological right humerus fracture 
one year prior to this presentation. 
 Examinations revealed vision of 
counting finger OS (left eye). Relative 
Afferent Pupilary Defect was positive 
with restrictions of extraocular muscle 
movements in all gazes. There was a 
protruding mass on the upper eyelid 
which was non tender and was fixed to 
the overlying and underlying structure, 
causing a non-axial proptosis, 
hypotropia, lagophthalmos and a 
resultant exposure keratopathy (Figure 
1a). The mass was firm on palpation 
and extended from the superior orbital 
rim towards the lid margin. Intraocular 
pressure was 24 mmHg OS and 11 
mmHg OD (right eye). The left optic 
disc was swollen and hyperaemic; 
and vessels were tortuous and dilated. 
The mass effect caused choroidal 
folds around the arcades and macular 
striations.
 A computed tomography (CT) scan 
was done and it revealed a left orbital 
mass with local involvement and 
with the presence of a multiple lytic 
lesions of the skull vault (Figure 2b). 
Magnetic resonance imaging (MRI) 
showed a tissue mass superior to the 
globe extending from the left frontal 
sinus and compressing the globe and 
optic nerve downwards (Figure 3a-3d). 
There was no globe or optic nerve 
infiltration noted. A tissue biopsy 
revealed multiple tissue fragments 
infiltrated by neoplastic plasma cells 
which were positive for CD138 and 
Kappa light chain restriction suggestive 
of a secondary extramedullary 
plasmacytoma of the orbit (Figure 
4). The patient completed 40 Gy/20 
fragments of radiotherapy and is 
currently undergoing chemotherapy. 
The swelling improved tremendously 
after receiving the current treatment 
(Figure 1c). However, her vision 
remained poor with light perception 
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OS. The patient succumbed to death 
at seven months of diagnosis. 
DISCUSSION
Multiple myeloma (MM) is a 
malignant neoplasm of the plasma 
cells characterized by monoclonal 
expansion of lymphoplasmacytic 
cells in the bone marrow. It affects 
many organ systems and typically 
presents with bone lesions, anaemia, 
hypercalcemia, kidney disease, bone 
marrow failure and various infections 
(Turaka 2014; Fung et al. 2005). 
Neoplastic plasma cell tumours 
arising in soft tissues without primary 
osseus involvement is normally 
known as primary extramedullary 
plasmacytoma (Aboud et al. 1995). 
Plasmacytoma of soft tissues is not 
a common manifestation of MM. 
Figure 1: a) Demonstrating the left upper eyelid swelling at presentation; b) Post excision biopsy; c) 
Shrinkage of the swelling post radiotherapy and while undergoing chemotherapy
Figure 2: a) and b) Lytic lesions of the skull bone on skull x-ray and CT brain; 
c) lytic bone lesions on knee x-ray; d) right pathological ulnar fracture with multiple lytic lesions.
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Orbital involvement by secondary 
plasmacytoma is rare and considered 
as worse prognosis for systemic 
morbidity (Shinder et al. 2010). Most 
patients who developed orbital 
myeloma are from the primary 
extramedullary plasmacytoma (PEP) 
group. About 50% will develop MM 
later in life. However, our case is a rare 
occurrence in which our patient has an 
underlying multiple myeloma and later 
developed secondary extramedullary 
Figure 3: MRI showing a mass extending from the left frontal sinus compressing the left orbit causing 
downward displacement and proptosis of left orbit
Figure 4: Histopathological examination of eyelid mass. a) H&E stain showed diffuse sheet of 
neoplastic plasma cells with eccentrically located nuclei; Kappa (b) and lambda (c) stain showed 
kappa light chain restriction; d) Cells stained brown show positive CD138 marker.
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plasmacytoma of the orbit with the 
presence of myeloma bone disease. 
 The pathophysiology of MM involves 
excessive production of monoclonal 
immunoglobulins and uncontrolled 
neoplastic plasma cells proliferation 
in the bone marrow. Classification of 
myeloma is based on the type of the 
abnormal immunoglobulins produced. 
IgA is the second commonest type 
after IgG followed by IgM. The rarer 
types are IgD and IgE. The Bence-
Jones protein found in the urine is 
due to the presence of light chains 
immunoglobulins (kappa or lambda) 
(Chin et al. 2011). The diagnostic criteria 
for MM are based on The International 
Myeloma Working Group criteria. 
It requires the presence of at least 
10% plasma cells on bone marrow 
examination or monoclonal plasma 
cells of a tissue biopsy, presence of 
serum or urine monoclonal protein, and 
evidence of end-stage organ damage 
which is defined as hypercalcaemia, 
renal failure, anemia and bony lesions 
(Chin et al. 2011).
 Orbital MM can present as three 
different entities. Each of these lacks 
certain findings that normally present 
in multiple myeloma with systemic 
involvement. The three different entities 
are plasmacytoma, primary/solitary 
extramedullary plasmacytoma (PEP) 
and necrobiotic xanthogranuloma 
(NXG). Plasmacytoma occurs as an 
isolated tumour in the absence of 
other skeletal lesions. The tumour 
is made up of monoclonal plasma 
cells. It responds well to radiotherapy 
and has better prognosis than MM. 
PEP is a plasma cell malignancy that 
develops in soft tissues rather than 
bone. It is commonly found in the 
upper respiratory tract and invasion 
into the orbit is due to spread from the 
surrounding sinuses. PEP has better 
prognosis than MM in which it has a life 
expectancy of eight years as compared 
to 24 months in patients with MM. 
 MM frequently affects the eyes. 
Common ocular findings are crystal or 
copper deposits on the cornea, ciliary 
body cyst, retinal haemorrhages and 
exudative macular detachment which 
were not present in our patient. The 
two pathophysiological process of 
ocular manifestations are infiltration 
of tissue cells by plasma cells and 
haematological abnormalities from 
increased blood viscosity (Burkat et al. 
2009). 
 Histopathological findings may 
reveal round plasma cells. It has 
an eccentric nucleus with prominent 
nucleolus (Figure 4a).  The characteristic 
of a clear area (Hoffa clear zone) 
next to the nucleus represents the 
prominent Golgi apparatus involved 
in production of immunoglobulin. 
Immunohistochemistry and flow 
cytometry helps in confirming 
monoclonality and differentiate 
MM from other lymphoproliferative 
diseases. In myeloma, the cells are 
usually CD56, CD38 and CD138 
positive and CD19 and CD45 negative 
(Figure 4d). Identifying the heavy- 
and light-chain restriction (Figure 4b 
& 4c) can be done using the in situ 
hybridization (Chin et al. 2011). 
 The mass effect of the lesion caused 
compression to our patient’s left globe 
and optic nerve which gave rise to 
the secondary increase in intraocular 
pressure and optic neuropathy. It also 
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caused lagopthalmos and proptosis 
with subsequent exposure keratopathy.
The myeloma bone disease is usually 
quite severe due to the multiple factors 
that contribute to the osteoclastic 
bone destruction and blocking of 
bone repair (Giuliani et al. 2004). 
Increase in osteoclastic activity is 
the primary cause of abnormal bone 
remodelling. This abnormal bone 
remodelling occurs in proximity to the 
active myeloma cells with a decrease 
in surrounding osteoblasts activity 
(Giuliani et al. 2004; Kristinsson et 
al. 2011). In contrast to myeloma 
bone disease, there are areas of 
bone without tumour involvement in 
myeloma patients which has balanced 
bone remodelling and an increased 
osteoclastogenesis combined with 
normal-to-increased bone formation. 
Permanent scarring of the bone can 
also be found in MM patients. Patients 
in remission may have persistent lytic 
lesions with no evidence of infiltration 
of the malignant myeloma cells in the 
bone marrow (Anderson et al. 2002). 
All these process contribute to lytic 
bone disease and causing pathological 
fracture in our patient.
 Reports stated that the interval to 
development of orbital lesions since 
the primary diagnosis of MM is an 
average of 18 months (Chin et al. 
2011; Burkat et al. 2009). However, 
our patient developed EMP of the 
orbit approximately 31 months after 
diagnosis of MM with presence of 
myeloma bone disease and succumbed 
to death 7 months later. 
 Radiotherapy has been proven to be 
effective in improving the symptoms by 
decreasing the size of lesions (Turaka 
2014) as seen in our patient. The mass 
shrunk tremendously and improved 
the anatomical outcome of the patient 
despite her poor visual outcome. 
Treatment of the orbital lesions 
includes local excision as a salvage 
surgery, exenteration or radiotherapy 
and additional chemotherapy (Turaka 
2014). In summary, our patient survived 
38 months after the diagnosis of MM 
and only survived seven months 
after the diagnosis of secondary 
extramedullary plasmacytoma of the 
orbit. Though the radiotherapy and 
chemotherapy helped in improving 
anatomical outcome of our patient, she 
eventually died despite the aggressive 
treatment given.
CONCLUSION
Orbital MM depicts a more aggressive 
disease as compared to extraorbital 
plasmacytomas or primary/solitary 
extramedullary plasmacytoma (PEP).
MM with orbital involvement is 
associated with poor prognostic 
outcome. Early detection may assist 
in early referral to the oncology/
hematology team and may help 
in preventing the debilitating 
complications and thus help in 
improving the patient’s quality of life.
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